Previous 10 | Next 10 |
MediWound Ltd. (MDWD) Q1 2019 Results Earnings Conference Call May 21, 2019, 8:30 AM ET Company Participants Jeremy Feffer - Managing Director Steve Wills - Chairman Sharon Malka - Chief Executive Officer Conference Call Participants Raj Denhoy - Jefferies Josh Jennings -...
YAVNE, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the f...
MediWound (NASDAQ: MDWD ) has out-licensed exclusive rights to debridement agent NexoBrid to Vericel (NASDAQ: VCEL ) in North America. More news on: MediWound Ltd., Vericel Corporation, Healthcare stocks news, Stocks on the move, Read more ...
$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones Leverages Vericel’s Commercial Capabilities and Presence in U.S. Burn Care Market Biologics License Application (BLA) Filing Planned for Fourth Quarter of 2019 Company to Host a Conference ...
YAVNE, Israel, March 26, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has filed its annual report on Form 20-F for the ...
MediWound Ltd. (MDWD) Q4 2018 Earnings Conference Call March 25, 2019 9:00 am ET Company Participants Steve Wills - Active Chairman of the Board Gal Cohen - President, Chief Executive Officer Sharon Malka - Chief Financial Officer Jeremy Feffer - Investor Relations Conferen...
MediWound (NASDAQ: MDWD ): Q4 EPS of $0.22 may not be comparable to consensus of -$0.15. More news on: MediWound Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Met Primary and All Secondary Endpoints in its Pivotal Phase 3 Study (DETECT) in NexoBrid ® for Eschar Removal of Severe Thermal Burns Awarded Additional BARDA Contract Valued up to $43 Million for the Development of NexoBrid for Sulfur Mustard Injuries Conference call begin...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The increasingly hot market for online video delivery is set to take another sharp ...
News, Short Squeeze, Breakout and More Instantly...
YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the second quarter ended June 30, 2024 on Wednesday, August 14, 20...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....